Logo

Synthego: Robert Deans and John Tan

Aug 26, 2020

Synthego has appointed Robert Deans as CSO and John Tan as chief operating officer.

Deans has more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise. He previously served in executive roles at BlueRock Therapeutics and Rubius Therapeutics, where he participated in the creation of next-generation therapies through the use of pluripotent stem cell biology and gene editing tools, Synthego said.

Tan has decades of global operations and automation expertise in various technology and life sciences companies, including Amazon and Thermo Fisher Scientific. At Thermo Fisher, he managed global planning, quality, regulatory, procurement, supply chain, and continuous improvement functions across more than 20 sites in the US, Europe, and Asia.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.